New imaging agent aims to better detect returning brain metastases

NCT ID NCT06777433

Ongoing Diagnosis Sponsor: Radiopharm Theranostics, Ltd Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 20, 2026 · Updated 22 times

Summary

This study tests a new imaging drug called RAD101, used with a PET scan, to see if it can better detect brain metastases that have come back after treatment. About 30 adults with certain cancers (like lung, breast, or melanoma) and a history of brain tumors will receive one dose of RAD101 and have a PET scan. The results will be compared with standard MRI scans to see if RAD101 improves detection of recurrent tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASES FROM SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Ascension Illinois Oncology Research

Hoffman Estates, Illinois, 60169, United States
BAMF Health

Grand Rapids, Michigan, 49503, United States
Goshen Center for Cancer Care

Goshen, Indiana, 46526, United States
Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States

Conditions

Explore the condition pages connected to this study.

BRAIN METASTASES FROM SOLID TUMORS